Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)

NCT01959945 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

219

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza

Interventions

BIOLOGICAL: Flublok® Quadrivalent Influenza Virus Vaccine
BIOLOGICAL: Fluarix Quadrivalent® Influenza Virus Vaccine

Sponsor

Protein Sciences Corporation